GlassScriptPhysician profile
Muhammad A Mustafa
NPI 1932480688
$23,939.10
in general payments reported to CMS, 2019-2025
34 companies · $1,422 in 2025
The $1,422 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $5,628 · 2021: $1,474 · 2022: $1,156 · 2023: $1,482 · 2024: $1,056 · 2025: $1,422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,924 · Education: $34.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,924.26 |
| Education | $34.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $13,015.05 | 2019-2025 | |
| Coala Life INC | $2,713.94 | 2020 | |
| Boston Scientific Corporation | $1,417.10 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Latitude Communicator Power Supply, Resonate El Icd Vr |
| Amgen INC. | $1,056.51 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $852.75 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $741.78 | 2019-2025 | Farxiga, Lokelma |
| Merck Sharp & Dohme LLC | $680.91 | 2021-2023 | Verquvo, Belsomra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $606.00 | 2019-2025 | Lifevest |
| Pfizer INC. | $482.66 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $470.18 | 2019-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $328.52 | 2021-2025 | Tyrx, Linq II, Cobalt Dr Mri Surescan |
| Amarin Pharma, INC. | $306.24 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $269.99 | 2019-2022 | |
| Esperion Therapeutics, INC. | $155.63 | 2020-2025 | Nexletol |
| Astellas Pharma US INC | $147.40 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $121.19 | 2022-2025 | Onpattro |
| Novo Nordisk INC | $75.03 | 2023-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $49.39 | 2019-2020 | |
| Kestra Medical Technology Services, INC. | $48.54 | 2024-2025 | Assure Wcd |
| Sanofi-Aventis U.S. LLC | $45.76 | 2019 | |
| Scpharmaceuticals INC. | $43.41 | 2024 | |
| Vantive US Healthcare LLC | $40.48 | 2025 | Renal - Pd |
| Regeneron Healthcare Solutions, INC. | $38.38 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.81 | 2021 | |
| Bracco Diagnostics INC. | $36.95 | 2022-2023 | |
| W. L. Gore & Associates, INC. | $22.86 | 2019 | |
| Medtronic Vascular, INC. | $22.84 | 2019 | |
| Bridgebio Pharma, INC. | $21.52 | 2025 | Attruby |
| Baxter Healthcare | $17.32 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Genzyme Corporation | $16.30 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $15.85 | 2019 | |
| Philips North America LLC | $14.45 | 2025 | Extended Holter |
| Portola Pharmaceuticals, LLC | $13.77 | 2019 | |
| Infobionic, INC | $12.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Mustafa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.